POWERFUL BLEED PROTECTION WITH THE ONLY FIX FDA APPROVED FOR UP TO 14-DAY DOSING*

#1 FACTOR IX CHOICE When Changing Therapy
#1 FACTOR IX CHOICE When Changing Therapy

*In patients 12 years and older on a weekly dose of ≤40 IU/kg for 1 month without spontaneous bleeding.

Zero median annualized spontaneous bleeding rate (AsBR) when dosed at 7 or 14 days in clinical trials.

Steady-state levels measured FIX at trough levels before each infusion every four weeks until week 92 at 7-day prophylaxis and
week 104 at 14-day prophylaxis. FIX levels were 13% when dosed every 14 days.

background

RESOURCES FOR YOU AND YOUR PATIENTS

CSL Behring is committed to providing treatments and supportive services that make a meaningful difference in the lives of people with bleeding disorders.

Resources available to help your patients get the treatment they need for hemophilia B include:

  • A free 30-day trial of IDELVION
  • Co-pay assistance for IDELVION prescriptions and refills
  • Reimbursement and access support
background

References: 1. Hemophilia FIX Market Assessment, Third-Party Market Research. 2. Data on file. Available from CSL Behring as DOF IDL-002.

You are now leaving the current website.

Do you want to continue?

No Yes